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Dear Editors of Journal of Clinical Neuroscience,
Enclosed please find a manuscript entitled “The use of TMZ embedded hydrogels for the 
treatment of orthotopic human glioma xenografts.” We are submitting this manuscript as an 
original research article to Journal of Clinical Neuroscience. 
In this manuscript, we report a novel approach to overcoming the challenge posed by the blood 
brain barrier in the treatment of glioma with chemotherapy. We found that by loading TMZ into 
a hydrogel matrix, the efficacy of TMZ against glioblastoma was enhanced. This was consistent 
between in vitro and in vivo animal models, with low cytotoxicity. We believe this technique 
may offer the opportunity to coat the inner lining of the glioma resection cavity and potentially 
decrease the rate of tumor recurrence when applied to larger animals.
 
We believe that these findings are of interest to the clinical neuroscience community and that the 
manuscript describing this work would be of interest to your readership. Thank you for your 
consideration.
The contents of this manuscript have not been copyrighted or published previously. All authors 
agree that the contents of this manuscript will not be copyrighted, submitted, or published 
elsewhere while acceptance by the Journal is under consideration. There are no directly related 
manuscripts or abstracts, published by any author(s) of this paper.
Sincerely,
Clark C. Chen, M.D., Ph.D.
Associate Professor, Neurosurgery
University of California, San Diego
3855 Health Science Drive #0987
La Jolla CA 92093-0987
Phone: 858-246-0674
Fax: 858-534-8899
Email: clarkchen@ucsd.edu
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma 
xenografts
Bandita Adhikari, Jie Li, Michael G Brandel, Diahnn Futalan, Johnny Akers, Timothy Deming, Clark 
C Chen, Bob S Carter
Abstract
 
The current treatment of glioblastoma multiforme (GBM) is limited by the restricted 
arsenal of agents which effectively cross the blood brain barrier (BBB). For example, 
only a fraction of Temozolamide (TMZ) administered systemically is available for 
therapeutic effect because of the BBB and the instability of TMZ under physiologic 
conditions. A novel approach to overcome this obstacle is to bypass the BBB and locally 
deliver chemotherapeutic agents directly to the tumor mass. We have explored the 
loading of TMZ into a novel hydrogel matrix, which can be delivered in liquid form and 
then solidifies in situ and releases chemotherapy as the matrix dissolves. Here, we 
tested the effect of amphiphilic diblock copolypeptide hydrogels (DCHs) of 180-poly-
lysine and 20-poly-leucine (K180L20) on TMZ using Glioblastoma models. In both the in 
vitro model, which involved treatment of a human glioblastoma GSC line suspended as 
neurospheres, and in vivo using an orthotopic glioma xenograft mouse model, we found 
that K180L20 could safely enhance the efficacy of TMZ. This technique may offer the 
opportunity to ‘coat’ the inner lining of the cavity following glioma resection with a slow-
release TMZ and potentially decrease recurrence. Future studies in larger animals are 
needed to delineate this effect. 
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Introduction
 
Glioblastoma multiforme (GBM) is the most common and most aggressive primary 
malignant brain tumor [1, 2]. The current standard treatment is surgical resection, 
followed by adjuvant radio- and chemo-therapy [1-3]. However, the median survival is 
only approximately 15 months [1-3]. The failure of cancer therapy is multifactorial 
including a genetically evolving tumor that escapes initial therapy and the restricted 
arsenal of agents which effectively cross the blood brain barrier (BBB) [4-6].
 
Temozolomide (TMZ) chemotherapy has been a significant advance in the 
chemotherapy of GBM [3, 6].  TMZ is administered systemically (oral or intravenous); 
however, only a fraction of total administered drug is available for therapeutic effect 
because of the BBB and the instability of TMZ under physiologic conditions [6, 7]. In 
brief, TMZ crosses the BBB into the brain cells, hydrolyses into DNA alkylating agent 5-
(3-methyl-triazen-1-yl)imidazole-4-carboxamide (MTIC) and causes cytotoxic damage to 
DNA [8]. TMZ can also degrade to MTIC in the bloodstream, which is problematic for 
treatment as MTIC does not cross the BBB and may cause hematologic toxicity [7]. Due 
to short half-life and poor penetration through the BBB, the patients must be 
administered with high doses of TMZ for a long period, which can lead to serious 
systemic toxicity [3, 6].
 
To overcome this obstacle, a novel approach is to bypass the BBB and locally deliver 
chemotherapeutic agents directly to the tumor mass.  As an alternative approach to 
systemic delivery of TMZ, in the current report we have explored the loading of TMZ into 
a novel hydrogel matrix, which can be delivered in liquid form and then solidifies in situ 
and releases chemotherapy as the matrix dissolves [9, 10]. This strategy was chosen 
based on reports that amphiphilic diblock copolypeptide hydrogels (DCHs) are capable 
of releasing chemotherapeutic agents in a rate-dependent manner by loading them in 
the matrix [9, 10]. Among these hydrogels, DCHs of 180-poly-lysine and 20-poly-leucine 
(K180L20) have been shown to have low cytotoxicity, controlled release of loaded drugs 
and biodegradability [9, 10]. Here, we tested the effect of K180L20 on TMZ using 
Glioblastoma models and the result indicated that K180L20 could enhance the efficacy of 
TMZ significantly both in vitro and in vivo.
 
Results
 
K180L20 is not toxic, in vitro and in vivo
 
To examine the toxicity of K180L20, NHA cells and GBM001 neurospheres (NSs) were 
treated in cell culture with Vehicle (PBS), TMZ (100µM), K180L20 (0.01%) or K180L20 
(0.01%)/TMZ (100µM), separately (Fig. 1A).
 
In both cell types, K180L20 alone did not show significant cytotoxicity. However, in NS 
cells, K180L20/TMZ decreased the viability from 60% to 20% compared to TMZ treatment 
alone, indicating that K180L20 might enhance the efficacy of TMZ specifically in tumor 
cells. Furthermore, orthotopic implantation of 4 µL of K180L20 (0.5%) with or without TMZ 
(50mM) treatment into Nu/Nu mice did not cause notable cell death detected by H&E 
staining (Fig. 1 B), or significant inflammation response by CD11b staining (Fig. 1C).
K180L20 enhances the efficacy of TMZ
 
Next, we investigated the role of K180L20 in the efficacy of TMZ in vivo using an 
orthotopic glioma xenograft mouse model. GBM001 cells stably transduced with 
GFP/Luc were implanted into Nu/Nu mice, followed by the treatment with 4 µL of vehicle 
(PBS), K180L-20 (0.5%), TMZ (50mM) or K180L-20 (0.5%)/TMZ (50mM), separately. 11 
days post treatment, IVIS BLI images were taken to evaluate the tumor size (Fig. 2A). 
Consistent with in vitro result, though tumors in K180L20 group were comparable to the 
ones in vehicle group, combination of K180L20 and TMZ dramatically decreased tumor 
size compared treatment with TMZ alone. Moreover, H&E staining showed significant 
shrinkage of tumor in the K180L20/TMZ group (Fig. 2B), indicating that K180L20 -could 
enhance the efficacy of TMZ in vivo.
Finally, the median survival of mice implanted with GBM001 was 20 days in both vehicle 
and K180L20 groups, which was prolonged to 28 days by TMZ treatment (Fig. 3). 
Combination of K180L20 and TMZ extended the median survival to 38 days, significantly 
(p=0.0285) (Fig. 3). 
 
Materials and Methods
Materials
 
Normal Human Astrocytes (NHA) were purchased from Sciencell, and GBM001 was 
established as a glioblastoma GSC line derived from a patient specimen and underwent 
<10 passages before use. Both cell lines were passaged at 37°C and 5%CO2. NHA 
was cultured in Astrocyte medium (ScienCell) supplemented with FBS, astrocyte growth 
supplement and penicillin/streptomycin. GBM001 was maintained as tumor spheres in 
neurobasal medium (DMEM F12/Glutamax, Gibco) supplemented with B-27, Glutamax, 
0.2% Heparin, EGF and FGF according to the manufacturer’s instruction. GFP/Luc 
Lentiviral construct was generously provided by Dr. Dong-Er Zhang (University of 
California, San Diego). Temozolomide (TMZ) was purchased from AK Scientific and 
freshly prepared for experimental use. D-luciferin firefly (Xenogen, XR-1001) was 
purchased from PerkinElmer. Peptide based hydrogel Lysine180 leucine 20 (K180L20) 
was provided by Amicrobe, Inc.
 
Drug Formulation
K180L20 was dissolved in PBS at 1% overnight at 37°C and vortexed rigorously to ensure 
a homogenous solution. Final concentration of K180L20 was 0.01% for the experiments in 
vitro and 0.5% for in vivo.
Transduction
 
GFP/Luc lentiviral particle was packaged using previously described methods [11]. 
GBM001 cells were transduced by GFP/Luc lentivirus for 3 days. Stable cells were 
generated by flow cytometric sorting using GFP.
 
Cell Viability Assay
 
Cells were plated in 96-well plates followed by the treatment with Vehicle (PBS), K180L20 
(0.01%), TMZ (100µM) or K180L20 (0.01%)/TMZ (100µM) formulation, separately. 5 days 
post-treatment, cellular viability was determined by CellTiter-Blue assay (Promega).
Orthotopic xenograft model
 
All animal procedures were performed in accordance with the requirements and 
recommendations in the Guide for the Care and the Use of Laboratory Animals 
approved by UCSD Institutional Animal Care and Use Committee (IACUC) and National 
Institute of Health (NIH).
5-6 weeks old Nu/Nu mice were injected orthotopically by 2x10^4 GBM001 cells 
transduced with GFP/Luc. The coordinates were 1.8 mm to the right of bregma and 3 
mm deep from the dura. 7 days post injection, mice were stereotactically injected with 4 
µl of vehicle, K180L20 (0.5%), TMZ (50mM) or K180L20 (0.5%)/TMZ (50mM) formulation, 
separately. Mice with >20% reductions in body weight were sacrificed, and brains were 
processed for paraffin or frozen section.
 
IVIS Imaging
 
Bioluminescent images (BLI) were taken at 11 days post-treatment under Xenogen IVIS 
200. D-luciferin (150mg/kg body weight) was administered into the mice via 
intraperitoneal (IP) injections and allowed to react for 10 minutes before imaging. 
Animals were then anesthetized with 2.5% Isoflurane and imaged under CCD camera; 
exposure time 0.2 sec, binning 8, field of view E (26.5 cm), f/stop (1), and emission filter 
open. Signal was measured and recorded as total flux (photons/sec). The results were 
then analyzed using Living Image Software (3.0).
 
H&E and Immunohistochemical (IHC) staining
 
Mice brains were harvested at 11 days post-treatment, followed by fixation using 4% 
PFA. The brains then were embedded in paraffin and sectioned in the UCSD Histology 
core. The slides were processed for H&E and IHC staining, separately. For IHC 
staining, the slides were stained with rabbit anti-CD11b antibody (1:200, Abcam), 
followed by anti-rabbit alkaline phosphatase secondary antibody (Vector Laboratories).
 
Discussion
 
In the present study, we demonstrated that K180L-20 could enhance TMZ efficacy both in 
vitro and in vivo in glioblastoma. Given the characteristics of diblock copolypeptide 
hydrogels (DCH) to deliver hydrophobic molecules directly into the brain and control the 
molecular release, we hypothesized that DCH might influence the efficacy of the loaded 
hydrophobic drug [9]. We loaded TMZ as the hydrophobic drug into the K180L20 DCH 
polymer and performed in vitro studies on Astrocytes and tumor cells, and in vivo study 
in nude mice. Both in vitro and in vivo studies showed minimal or no toxicity and 
enhanced efficacy of TMZ with K180L20. These observations suggest that K180L20 is 
innocuous and does indeed enhance the efficacy of TMZ. The enhancement in the 
efficacy of TMZ, based on previous findings, can be attributed to drug release kinetics of 
DCHs. DCHs can release loaded hydrophobic drugs with a certain release profile, and 
the kinetics of release depend upon the qualitative and quantitative formulations of the 
drug and polymer [9]. Prior studies by T. Deming et al. have shown that higher 
concentrations of DCH prolonged the drug release profile; 4% K180L20 showed the most 
prolonged drug release profile followed by 3% and then by 2% in in-vitro studies [9]. In 
our study, only 0.5% K180L20 was enough to bring about the change in the in vivo study 
with a median survival of 38 days in K180L20/TMZ group versus 28 days in TMZ group. 
We believe using a higher concentration of K180L20 could have prolonged the median 
survival, but limitations of DCH in solubility and injectability play a vital role in executing 
such studies. One of the problems noted during our study was that the DCH polymer 
provided by Amicrobe, Inc. was not dissolvable at 3% by volume in water. Also, the 
dissolved hydrogel polymer tends to solidify at room temperature; therefore, maintaining 
the hydrogel/drug formulation at 37°C at all times during the experiment might be a 
useful approach. In terms of solubility of DCHs, an easier and readily dissolvable 
method for K180L20 DCHs needs to be developed in order to be able to inject higher 
concentrations of DCH for more sustained drug release.
Following resection of human glioma (either total or subtotal), a resection cavity is 
present. Prior studies have shown that typically, initial recurrence of glioma occurs 
within 2 cm of this resection cavity (12).  This has been the rationale behind the 
development of chemotherapy embedded wafers which are placed in the resection 
cavity following surgery in place of or to enhance the efficacy of systemically delivered 
chemotherapy. The K180L20 DCHs offer interesting alternatives in this regard in that the 
polymer is initially extruded into the resection cavity in a liquid form and then solidifies.  
This offers the opportunity to have a more conformal chemotherapy embedded polymer, 
with the ability to ‘coat’ the inner lining of the resection cavity with a slow-release TMZ.  
Future studies in larger animals will better delineate the performance characteristics for 
recurrence prevention of larger volumes of the polymer in the context of glioma 
resection. 
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Figure Captions:
 
Fig 1. Toxicity of K180L20 in Normal Human Astrocytes (NHA) and GBM001 
neurospheres. (A) CellTiter-Blue Survival Assay. NHA and GBM001 neurospheres 
(2x10^3 cells per well) were treated with K180L20 (0.01%), TMZ (100µM), or K180L20 
(0.01%)/ TMZ (100µM), and cellular viability was measured 5 days after the treatment. 
(B) H&E Staining. Nu/Nu mice were intracranially injected with K180L20 (0.5%) or K180L20 
(0.5%)/TMZ (50µM) and sacrificed 1 day post injection. (C) Immunohistochemical (IHC) 
staining. The brain sections from (B) were stained with anti-CD11b antibody (1:200, 
Abcam), followed by anti-rabbit alkaline phosphatase secondary antibody (Vector 
Laboratories).
 
Fig 2. K180L20 enhances the efficacy of TMZ in vivo. (A) Representative 
bioluminescent Images. 2×10^4 GFP/Luc transduced GBM001 neurospheres were 
implanted into Nu/Nu mice stereotactically. 7 days post-tumor-implantation, animals 
were treated with Vehicle (PBS), TMZ (50mM), K180L20 (0.5%) or K180L20 (0.5%)/TMZ 
(50µM), separately. IVIS images were taken 11 days post-treatment and mice were 
sacrificed for IHC staining. (B) H&E staining. The brain sections from (A) showed 
variable tumor size among 4 different treatment groups.
Fig 3. Kaplan-Meier Survival Curve. Nu/nu mice were implanted intracranially as 
described in Fig 2. 7 days post-implantation, mice were treated with vehicle (n=12), 
TMZ (50mM) (n=12), K180L20 (0.5%) (n=12) or K180L20 (0.5%)/TMZ (50µM) (n=11), 
separately. The percentage of surviving mice (y-axis) is plotted with respect to time in 
days (x-axis). Note: p-value of TMZ (50mM) vs. K180L20 (0.5%) /TMZ(50µM) is 0.0285.
 



Highlights
 Therapeutic effect of systemic Temozolomide is limited by the blood brain barrier.
 Temozolomide can be loaded onto a novel hydrogel matrix.
 Hydrogels locally deliver TMZ to the tumor mass and bypass the BBB.
 The hydrogels tested are not toxic in vitro or in vivo.
 The efficacy of TMZ in glioblastoma models is enhanced by hydrogel delivery. 
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